4.7 Meeting Abstract

Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?

Journal

ANNALS OF ONCOLOGY
Volume 33, Issue 7, Pages S787-S788

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.07.656

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available